| You
are here: Home: BCU 1|2003: A
CME Audio Series and Activity
Breast Cancer Update: A CME Audio Series and
Activity
Statement of Need /Target Audience
Breast cancer is one of the most rapidly evolving fields in medical
oncology. Published results from a plethora of ongoing clinical
trials lead to the continuous emergence of new therapeutic agents
and changes in the indications for existing treatments. In order
to offer optimal patient care — including the option of clinical
trial participation — the practicing medical oncologist must
be well informed of these advances. To bridge the gap between research
and patient care, Breast Cancer Update utilizes one-on-one discussions
with leading oncology investigators. By providing access to the
latest research developments and expert perspectives, this CME program
assists medical oncologists in the formulation of up-to-date clinical
management strategies.
Global Learning Objectives
Upon completion of this activity, participants should be able
to:
- Critically evaluate the clinical implications of emerging clinical
trial data in breast cancer treatment.
- Describe and implement an algorithm for HER2 testing and treatment
of patients with HER2-positive breast cancer.
- Develop a management strategy for women with ER-positive and
-negative breast cancers in the adjuvant, neoadjuvant and metastatic
settings.
- Counsel postmenopausal patients with ER-positive tumors about
the risks and benefits of aromatase inhibitors in the adjuvant
setting.
- Evaluate the relevance of emerging clinical trial data on dose-dense
adjuvant chemotherapy.
Issue 1, 2003 of Breast Cancer Update consists of discussions
with three research leaders on a variety of important topics including
aromatase inhibitors in the adjuvant setting, dose-dense chemotherapy,
ovarian ablation and the use of capecitabine.
Specific learning objectives for Issue 1
Upon completion of this activity, participants should be able
to:
- Describe the rationale for and results of clinical research
on dose-dense adjuvant chemotherapy.
- Counsel and make recommendations for individual ER-positive,
postmenopausal patients regarding the use of adjuvant aromatase
inhibitors.
- Discuss the ongoing/planned clinical trials of capecitabine
in the adjuvant and neoadjuvant settings.
- Describe the clinical implications of research on combinations
of chemotherapy with trastuzumab in women with HER2-positive metastatic
disease.
Accreditation Statement
This activity has been planned and implemented in accordance with
the Essential Areas and Policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint sponsorship
of the Postgraduate Institute for Medicine and NL Communications,
Inc. The Postgraduate Institute for Medicine is accredited by the
ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Postgraduate Institute for Medicine designates this educational
activity for a maximum of 3 category 1 credits toward the AMA Physician's
Recognition Award. Each physician should claim only those credits
that he/she actually spent in the activity.
Faculty Disclosure Statements
The Postgraduate Institute for Medicine has a conflict of interest
policy that requires course faculty to disclose any real or apparent
commercial financial affiliations related to the content of their
presentations/materials. It is not assumed that these financial
interests or affiliations will have an adverse impact on faculty
presentations; they are simply noted in this supplement to fully
inform participants.
|
